From 2018 to 2020, the marketing of Chinese-produced Class 1 new drugs entered the harvest period, with a total of 32 marketed (Chinese-produced Class 1 new drugs here refer to drugs registered under the classification of chemical drugs 1 and therapeutic biological products 1; preventive biological products and traditional Chinese medicines are not included in the statistics).
Chinese-produced Class 1 New Drugs Marketed in 2018
(Source: NMPA)
Chinese-produced Class 1 New Drugs Marketed in 2019
(Source: NMPA)
Chinese-produced Class 1 New Drugs Marketed in 2020
(Source: NMPA)
From the perspective of years, nine Class 1 new drugs were approved both in 2018 and 2019, and the number exploded in 2020 to reach 14.
From the perspective of R&D companies, from 2018 to 2020, Hengrui had the most Class 1 new drugs approved, with four, namely, pyrotinib maleate, camrelizumab, fluzoparib, and remimazolam tosylate, followed by Hansoh, with three approved, namely, polyethylene glycol loxenatide, flumatinib, and almonertinib. BeiGene, Ascletis, and Hutchison MediPharma all had two approved, and the rest had only one. There’s no doubt that Hengrui is still the leading innovative drug enterprise in China.
From the perspective of the approved indications, nearly half of the 32 Class 1 new drugs are oncology drugs, followed by anti-infectives and anesthetics, therefore, oncology drugs are still the top priority in the R&D of Chinese-produced Class 1 new drugs. And if you are looking for anesthesia distributors, then Pharmasources would be your best choice.
From the perspective of targets, amo...
(All Rights Reserved)